Archive for the ‘FDA Leadership’ Category
Thursday, August 26th, 2010
With Congress out of session until September 13, the Executive Branch has the opportunity to gain extra column inches and media bandwidth. Thus, last week’s report on medical countermeasures (MCM), released by HHS Secretary Sebelius, drew a lot of interest and a minimum of Congressional comment.
The Secretary released the findings and recommendations from a top-to-bottom review of the Department’s efforts with regard to the development of MCM. In the view of FDA Matters, the report thrusts FDA back into its rightful place as a key agency deserving more resources and respect for its national security responsibilities. (more…)
Tweet This Post
Posted in Drug Approval and Access, FDA Leadership, FDA and Congress | No Comments »
Sunday, August 15th, 2010
When my Smartphone delivered an e-mail at 5:12 p.m. on Friday: “FDA approv…,” I knew that FDA had just announced something controversial. All public relations people (including those at FDA) have been taught that late Friday is the time to release stories you don’t want to receive much attention.
Indeed, it was the 5-day emergency contraceptive pill, Ella, that was approved. So far, FDA seems to have achieved its goal of less coverage. But I was left wondering if the announcement required that treatment and why it led one advocate to describe the decision as “further evidence that the FDA is committed to restoring scientific integrity in its decisions.” (more…)
Tweet This Post
Posted in Drug Approval and Access, FDA Leadership, FDA and Industry | 1 Comment »
Sunday, August 8th, 2010
FDA supposedly swings back and forth between emphasizing “expedited approvals of promising therapies” and “extended pre-approval examination of every safety issue.” Current thinking is that FDA is now leaning more toward the safety end of this spectrum.
FDA Matters thinks a lot of this is perceptual. Approval decisions reflect FDA’s honest and relatively clear judgment on medical need, quality of the clinical data, and the risks and benefits of a specific product. Mostly, I can understand FDA’s decisions, even when I don’t agree. Still, there is a lot of tension within FDA and with various stakeholders about approvals versus safety risk. (more…)
Tweet This Post
Posted in Drug Approval and Access, FDA Leadership, FDA and Industry | No Comments »
Sunday, August 1st, 2010
Several generations of North American trained doctors were taught: if you hear hoofbeats, think horses not zebras. This graphic image reinforced an important aspect of medicine for young physicians seeing mostly severely ill patients in tertiary care hospitals: if an otherwise healthy patient is coughing, it is most likely a bad cold. It is almost certainly not pneumonic plague.
What Congress, FDA, and NIH have learned over the last 30 years is that there are many more medical zebras in the United States than anyone imagined. NIH has catalogued nearly 7,000 rare diseases. More are being discovered all the time. Altogether, it is estimated that 25 to 30 million Americans are affected by rare diseases. (more…)
Tweet This Post
Posted in Drug Approval and Access, FDA Leadership, Orphan Drugs | No Comments »
Sunday, July 25th, 2010
FDA is working on an approval pathway for bio-similars, re-examining the way medical devices are reviewed, trying to upgrade the quality and speed of generic drug reviews and will soon be evaluating its process for granting accelerated approvals to drugs.
These seemingly unconnected activities all have in common that they are supposed to be abbreviated processes to get new products to patients more quickly without risking safety or quality problems. FDA Matters thinks FDA should articulate its philosophy about how these short-cuts should work and what standards apply in all instances. (more…)
Tweet This Post
Posted in Drug Approval and Access, FDA Leadership, FDA and Industry | 1 Comment »
Sunday, July 11th, 2010
For the news media, the only FDA story this coming week will be the two-day advisory committee meeting reviewing the diabetes drug, Avandia. Based on an earlier article (link below), FDA Matters will be looking at how Dr. Hamburg’s FDA handles the discordant voices coming from within the agency.
Missing from public dialogue is the extraordinary (perhaps unprecedented) number of large, consequential projects that FDA will be working on this summer. Every part of FDA is involved in some initiative that could become a “game-changer” for the agency. (more…)
Tweet This Post
Posted in Drug Approval and Access, FDA Accountability and Transparency, FDA Leadership, FDA and Congress, FDA and Industry, FDA-NIH Relations, Follow-on Biologics, Food Issues, Orphan Drugs | No Comments »
Thursday, June 17th, 2010
It seems a rather uncontroversial proposition: FDA-regulated companies are responsible for their vendors, including every contracted piece of work that is done on the company’s behalf. If problems develop, it makes no difference whether a company did it…or a contractor did it for them. Two seemingly unrelated items this week suggest that FDA is becoming concerned about whether FDA-regulated companies are overseeing their vendors. (more…)
Tweet This Post
Posted in FDA Leadership, FDA and Industry, Insight on FDA-regulated Industries | 2 Comments »
Sunday, June 13th, 2010
Two weeks ago, FDA Matters explored Dr. Hamburg’s legacy, focusing on advocacy for resources, prioritizing regulatory science and upgrading enforcement. These will be accomplished before she leaves office. But is she making similar progress in creating “a new FDA?” (more…)
Tweet This Post
Posted in Drug Approval and Access, FDA Accountability and Transparency, FDA Leadership, Planning for FDA's Future | No Comments »
Thursday, May 27th, 2010
May 18 marked one year since Dr. Margaret Hamburg was sworn in as Commissioner of the US Food and Drug Administration. The challenges are great, the torrent of issues is never-ending and most days you can smile but you can’t win. Nonetheless, I think it has been a very good first year for her and for Principal Deputy Commissioner, Dr. Joshua Sharfstein.
It may seem premature to be discussing “the Hamburg legacy.” But you know that she is thinking about it (all commissioners do), so why can’t FDA Matters talk about it? (more…)
Tweet This Post
Posted in FDA Appropriations, FDA Leadership, FDA and Congress, FDA and Industry, Planning for FDA's Future | No Comments »
Sunday, May 23rd, 2010
FDA Matters is in favor of safe foods and safe medical products. Who isn’t? If you are a consumer, maybe that’s all that matters.
However, being in favor of safe foods and safe medical products is not enough if you are FDA, the media, Congressional authorizers and appropriators, OMB, and industry. It sounds good, but what does it really mean? In the FDA context, “safe” means many things, some of which are barely related to each other. (more…)
Tweet This Post
Posted in FDA Leadership, FDA and Industry, Food Issues, Planning for FDA's Future | 3 Comments »
© 2009-2010 by HPS Group. All rights reserved. Permission is hereby granted to those wishing to quote or reprint from this site, providing it is properly attributed to
FDA Matters: The Grossman FDA Report™.
